Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.37 |
| ▸ | DRD1 | P21728 | 1/20 | 0.37 |
| ▸ | DRD4 | P21917 | 1/20 | 0.37 |
| ▸ | DRD5 | P21918 | 1/20 | 0.37 |
| ▸ | DRD3 | P35462 | 1/20 | 0.37 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.34 |
| ▸ | NPC1 | O15118 | 2/20 | 0.34 |
| ▸ | RAB9A | P51151 | 2/20 | 0.34 |
| ▸ | APEX1 | P27695 | 4/20 | 0.34 |
| ▸ | MEN1 | O00255 | 3/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | RAD52 | P43351 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6787466 | 1.00 | DRD2 (0.37) | DRD2DRD1DRD4DRD5DRD3 | |
| Hydrogen Peroxide SCHEMBL7101046 | 0.89 | DRD2 (0.39) | DRD2DRD1DRD4DRD5DRD3 | |
| SCHEMBL6787801 | 0.89 | DRD2 (0.39) | DRD2DRD1DRD4DRD5DRD3 | |
| Hydrogen Peroxide SCHEMBL7101042 | 0.89 | DRD2 (0.39) | DRD2DRD1DRD4DRD5DRD3 | |
| SCHEMBL6787798 | 0.89 | DRD2 (0.39) | DRD2DRD1DRD4DRD5DRD3 | |
| SCHEMBL6783193 | 0.79 | HDAC6 (0.53) | MAPTKDM4EHDAC3HDAC4HDAC1 | |
| SCHEMBL6783587 | 0.78 | HDAC1 (0.44) | KMT2AMEN1ALDH1A1HDAC3HDAC1 | |
| SCHEMBL6344755 | 0.76 | NPC1 (0.66) | KMT2ANPC1RAB9AALDH1A1MAPT | |
| SCHEMBL6791391 | 0.76 | PPARA (0.35) | KMT2ANPC1RAB9APOLB | |
| SCHEMBL6791386 | 0.76 | PPARA (0.35) | KMT2ANPC1RAB9APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1286994-A1 | HYDROXAMIC AND CARBOXYLIC ACID DERIVATIVES HAVING MMP AND TNF INHIBITORY ACTIVITY | Darwin Discovery Limited (GB) | 2003-03-05 | — | — | EP | claimed |
| WO-2001087883-A1 | HYDROXAMIC AND CARBOXYLIC ACID DERIVATIVES HAVING MMP AND TNF INHIBITORY ACTIVITY | DARWIN DISCOVERY LIMITED (GB) | 2001-11-22 | — | — | WO | claimed |
| US-20040176362-A1 | Hydroxamic and carboxylic acid derivatives | BATTY DUNCAN (GB) | 2004-09-09 | — | — | US | disclosed |
| US-6734189-B2 | TETRAHYDRO-N-CARBOXYALKYLSULFONYLCARBOLINE DERIVATIVES, USEFUL FOR THE TREATMENT OF DISEASES MEDIATED BY INHIBITORS OF MATRIX METALLOPROTEINASE, ADAM, ADAM-TS ENZYMES, AND/OR TNF ALPHA -MEDIATED DISEASES | DARWIN DISCOVERY, LTD. (GB) | 2004-05-11 | — | — | US | disclosed |
| EP-1286994-A1 | HYDROXAMIC AND CARBOXYLIC ACID DERIVATIVES HAVING MMP AND TNF INHIBITORY ACTIVITY | Darwin Discovery Limited (GB) | 2003-03-05 | — | — | EP | disclosed |
| US-20030032652-A1 | Hydroxamic and carboxylic acid derivatives | BATTY DUNCAN (GB) | 2003-02-13 | — | — | US | disclosed |
| US-6469020-B2 | AS INHIBITORS OF MATRIX METALLOPROTEINASE, FOR THERAPY OF DISEASES SUCH AS DEGENERATIVE DISEASES AND CERTAIN CANCERS | DARWIN DISCOVERY, LTD. (GB) | 2002-10-22 | — | — | US | disclosed |
| US-20020013333-A1 | Hydroxamic and carboxylic acid derivatives | DARWIN DISCOVERY LIMITED (GB) | 2002-01-31 | — | — | US | disclosed |
| WO-2001087883-A1 | HYDROXAMIC AND CARBOXYLIC ACID DERIVATIVES HAVING MMP AND TNF INHIBITORY ACTIVITY | DARWIN DISCOVERY LIMITED (GB) | 2001-11-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020013333-A1 | Hydroxamic and carboxylic acid derivatives | HCAR2, HCAR1, CBR1 | DRD2 1333/4885DRD1 2328/4885DRD4 2437/4885 |
| US-20040176362-A1 | Hydroxamic and carboxylic acid derivatives | ADAM17, ADAM10, ADAM9 | DRD2 4648/4885DRD1 4580/4885DRD4 4468/4885 |
| US-20030032652-A1 | Hydroxamic and carboxylic acid derivatives | ADAM17, ADAM10, ADAM9 | DRD2 4648/4885DRD1 4580/4885DRD4 4468/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.